BioCentury
ARTICLE | Clinical News

Oral interferon-alpha lozenges: Phase II start

October 24, 2011 7:00 AM UTC

This quarter, Vita's CytoPharm Inc. subsidiary and Amarillo will begin a double-blind, placebo-controlled, Taiwanese Phase II trial to compare 150 IU oral interferon-alpha lozenges twice daily plus 75 mg oral Tamiflu oseltamivir twice daily for 5 days vs. Tamiflu alone in about 60 patients. Intas has Indian and Nepalese rights to Amarillo's oral interferon (see BioCentury, Oct. 12, 2009). CytoPharm has rights to develop the product for HCV, HBV and influenza in China and Taiwan, while Cyto Biotech has exclusive rights for all indications in other Asian countries (see BioCentury, March 9, 2009). ...